Interplay Between the p53 Tumor Suppressor Protein Family and Cdk5: Novel Therapeutic Approaches for the Treatment of Neurodegenerative Diseases Using Selective Cdk Inhibitors.

Interplay Between the p53 Tumor Suppressor Protein Family and Cdk5: Novel Therapeutic Approaches for the Treatment of Neurodegenerative Diseases Using Selective Cdk Inhibitors. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Interplay Between the p53 Tumor Suppressor Protein Family and Cdk5: Novel Therapeutic Approaches for the Treatment of Neurodegenerative Diseases Using Selective Cdk Inhibitors. Abstract Text:

Wesierska-Gadek,Joanna B Strosznajder,Gerald Schmid,

Cyclin-dependent kinases (Cdks) play a key role in orchestrating the coordination of cell cycle progression in proliferating cells. The escape from the proper control of the cell cycle by the upregulation of cyclins or aberrant activation of Cdks leads to malignant transformation. In quiescent cells and/or terminally differentiated cells, the expression pattern and activity of Cdks is altered. In postmitotic neurons, expression of mitotic kinases is downregulated, whereas Cdk5 expression becomes upregulated. Similarly to other Cdks, free Cdk5 displays no enzymatic activity and requires complex formation with a specific regulatory subunit. Two activators of Cdk5 have been identified. p35 and its isoform p39 bind to, and thereby activate, Cdk5. Unlike mitotic kinases, Cdk5 does not require activating phosphorylation within the T-loop. Because p35 is a short-lived protein, the p35/Cdk5 complexes are unstable. The stability of the p35 protein is regulated by its Cdk5-mediated phosphorylation of p35. Activated p35/Cdk5 kinase phosphorylates numerous physiological targets. The proper phosphorylation of the most important substrates, such as tau protein and neurofilament H, is essential for the correct regulation of the cytoskeletal organization, thereby regulating cell adhesion, motility, and synaptic plasticity. Moreover, Cdk5 regulates the activity of the p53 tumor suppressor via phosphorylation. p53 is upregulated in multiple neuronal death paradigms, including hypoxia, ischemia, and excitotoxicity, and plays a key role in the induction of apoptosis. On the other hand, an abnormally high expression and elevated activity of Cdk5 was observed in neurodegenerative diseases, suggesting the application of Cdk inhibitors for their therapy. Considering the action of some Cdk inhibitors on the expression and activity of the p53 protein, their therapeutic efficacy must be carefully evaluated.

Interplay Between the p53 Tumor Suppressor Protein Family and Cdk5: Novel Therapeutic Approaches for the Treatment of Neurodegenerative Diseases Using Selective Cdk Inhibitors. Publishing Authors By Initials

J Wesierska-Gadek,JB Strosznajder,G Schmid,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Interplay Between the p53 Tumor Suppressor Protein Family and Cdk5: Novel Therapeutic Approaches for the Treatment of Neurodegenerative Diseases Using Selective Cdk Inhibitors. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Molecular neurobiology

VOLUME: 34

Page Numbers: 27-50

Journal Abbreviation:

ISSN: 0893-7648

DAY: 27

MONTH: Aug

YEAR: 2006

Interplay Between the p53 Tumor Suppressor Protein Family and Cdk5: Novel Therapeutic Approaches for the Treatment of Neurodegenerative Diseases Using Selective Cdk Inhibitors. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8900963

Interplay Between the p53 Tumor Suppressor Protein Family and Cdk5: Novel Therapeutic Approaches for the Treatment of Neurodegenerative Diseases Using Selective Cdk Inhibitors. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Interplay Between the p53 Tumor Suppressor Protein Family and Cdk5: Novel Therapeutic Approaches for the Treatment of Neurodegenerative Diseases Using Selective Cdk Inhibitors. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Interplay Between the p53 Tumor Suppressor Protein Family and Cdk5: Novel Therapeutic Approaches for the Treatment of Neurodegenerative Diseases Using Selective Cdk Inhibitors.

AFFILIATION: Department of Medicine I, Institute of Cancer Research and Cell Cycle Regulation Group, Medical University of Vienna, Vienna, Austria.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Mol Neurobiol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Interplay Between the p53 Tumor Suppressor Protein Family and Cdk5: Novel Therapeutic Approaches for the Treatment of Neurodegenerative Diseases Using Selective Cdk Inhibitors Related Publications

• A conformational unfolding reaction activates phage fd for the infection of Escherichia coli.
• Carbon metabolism and product inhibition determine the epoxidation efficiency of solvent-tolerant Pseudomonas sp. strain VLB120DeltaC.
• Cerebral near-infrared spectroscopy in adult patients after cardiac surgery is not useful for monitoring absolute values but may reflect trends in venous oxygenation under clinical conditions.
• Characterization of the C-terminal ER membrane anchor of PTP1B.
• Characterization of the genotoxic potential of formaldehyde in V79 cells.
• Clinical observations of sertindole in 53 hospitalised patients with psychotic disorders.
• Clinical validation of a digital transcutaneous PCO2/SpO2 ear sensor in adult patients after cardiac surgery.
• Coarse-grained lattice model for investigating the role of cooperativity in molecular recognition.
• Detection and differentiation of wild-type and vaccine mutant varicella-zoster viruses using an Invader Plus method.
• Disorder-induced static antiferromagnetism in cuprate superconductors.
• Emerging drugs for biliary cancer.
• Emphysema and secondary pneumothorax in young adults smoking cannabis.
• Examples of Cross-Section Research on the Effect of the Built Environment on Physical Activity in Diverse Urban Communities: 246: 4:10 PM-4:35 PM.
• Groups of adjacent contour segments for object detection.
• Identification of a new porin, RafY, encoded by raffinose plasmid pRSD2 of Escherichia coli.
• Impact of the SMAS on Frey's syndrome after parotid surgery: a prospective, long-term study.
• Influence of comorbidity on outcome after pulmonary resection in the elderly.
• Inhibition of farnesyl protein transferase sensitizes human MCF-7 breast cancer cells to roscovitine-mediated cell cycle arrest.
• Interplay Between the p53 Tumor Suppressor Protein Family and Cdk5: Novel Therapeutic Approaches for the Treatment of Neurodegenerative Diseases Using Selective Cdk Inhibitors.
• Microbial biofilms: new catalysts for maximizing productivity of long-term biotransformations.
• New options in insulin therapy.
• Optimization of the gbeta1 domain by computational design and by in vitro evolution: structural and energetic basis of stabilization.
• Pediatric pet: indications and value of multimodal imaging.
• SNX9 couples actin assembly to phosphoinositide signals and is required for membrane remodeling during endocytosis.
• Screening and purification for novel cytochrome b5 from uncultured environmental micro-organisms.
• Site-directed mutagenesis of loop L3 of sucrose porin ScrY leads to changes in substrate selectivity.
• The dynamin middle domain is critical for tetramerization and higher-order self-assembly.
• [Cardiovascular impact of the autonomic neuropathy of diabetes mellitus]
• [On urinary tract infections after a single catheterization]
• [Suddenly occurring exercise intolerance]